Werewolf Therapeutics to Present at SITC 2026 Annual Meeting

WALTHAM, Mass., Oct. 30, 2026 /CourierPR/ -- Werewolf Therapeutics, an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, has been selected to present its research at the upcoming Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting, scheduled for November 4-8, 2026, in Phoenix, Arizona. The company will deliver an oral presentation and present two posters, highlighting its advancements in conditionally activated therapeutics.

This presentation is set for Saturday, November 7, 2026, from 2:30 to 2:45 p.m. Mountain Time (MT), and will take place in North Building - 300 Level, Halls BC. It is part of Session 205: Clinical Oral Abstract Session 2, which runs from 1:30 to 3:00 p.m. MT.

Additionally, Werewolf Therapeutics will present two posters. This poster will be available for viewing during the entire meeting, from Saturday, November 7, 2026, from 9 a.m. to 8:30 p.m. MT, in North Building - Lower Level, Exhibition Halls 4-6.

Werewolf Therapeutics, which is pioneering the development of conditionally activated therapeutics to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, has designed INDUKINE™ molecules that activate selectively in the tumor microenvironment. The company’s clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 and Interleukin-12 INDUKINE molecules, respectively, for the treatment of solid tumors.

The company’s participation in the SITC 2026 Annual Meeting underscores its commitment to advancing immunotherapy research and bringing innovative treatments to patients with cancer. The event will provide a platform for Werewolf Therapeutics to share its latest findings and engage with the broader immunotherapy community.

Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company, is dedicated to developing therapeutics that stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. The company’s INDUKINE™ molecules are designed to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment, addressing the limitations of conventional proinflammatory immune therapies.